Table 2.

Formulation of PfRipr5 with Alhydrogel^® and CAF^®01.

	Alhydrogel®	100 µg/mL PfRipr5+ Alhydrogel®	400 µg/mL PfRipr5+ Alhydrogel®	CAF®01	100 µg/mL PfRipr5+CAF®01	400 µg/mL PfRipr5+CAF®01
Appearance*	Opaque suspension	Opaque suspension	Opaque suspension	Opaque suspension	Opaque suspension	Opaque suspension
pH**	7.2	6.5	7.3	7.0	6.5	7.2
Non-adsorbed PfRipr5***	–	Below detection level of 25 µg/ml	Below detection level of 25 µg/ml	–	Below detection level of 25 µg/ml	Below detection level of 25 µg/ml

*Appearance was determined by visual inspection.

**pH of the final vaccine formulation was measured, as this may be an indicator of chemical stability.

***Non-adsorbed PfRipr5 protein concentration in the supernatant after the centrifugation was determined by BCA.